NCT01650012View on ClinicalTrials.gov

Eplerenone in Hemodialysis Trial

NACompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
HemodialysisEnd Stage Renal Disease
Interventions
DRUG

eplerenone

target 50 mg per day titrated down for hyperkalemia or hypotension

DRUG

Placebo

Placebo

Trial Locations (5)

Unknown

Calgary

Winnipeg

St. Joseph's Healthcare, Hamilton

London

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

McMaster University

OTHER

NCT01650012 - Eplerenone in Hemodialysis Trial | Biotech Hunter | Biotech Hunter